Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Platten

Showing results (1-10 of 352) with videos related to

Pageof 36
Sort By:
Nature|September 19, 2018
T cells engineered to home in on brain cancerMichael Platten
Neuro-Oncology|April 3, 2019
How to integrate immunotherapy into standard of care in glioblastomaMichael Platten
Therapeutic Advances in Neurological Disorders|February 23, 2019
Practice-changing developments in neuro-oncology: embracing heterogeneityMichael Platten
Neuro-Oncology|October 20, 2019
Driving mesenchymal transition in glioblastomaMichael Platten
Neuro-Oncology|October 24, 2017
EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?Michael Platten
Current Opinion in Neurology|September 8, 2025
Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?Michael Platten
Neuro-Oncology|December 17, 2021
How mutant isocitrate dehydrogenase orchestrates immune cellsLukas Bunse, Michael Platten
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Vaccines Targeting Gliomas: Antigens MatterMichael Platten, Niklas Grassl
The New England Journal of Medicine|January 8, 2025
Heating Up IDH-Mutant GliomasMichael Platten, Lukas Bunse
Neuro-Oncology|February 14, 2014
CMV infection and glioma, a highly controversial concept struggling in the clinical arenaWolfgang Wick, Michael Platten
Pageof 36

Showing results (1-10 of 352) with videos related to

Sort By:
Pageof 36
Nature|September 19, 2018
T cells engineered to home in on brain cancerMichael Platten
Neuro-Oncology|April 3, 2019
How to integrate immunotherapy into standard of care in glioblastomaMichael Platten
Therapeutic Advances in Neurological Disorders|February 23, 2019
Practice-changing developments in neuro-oncology: embracing heterogeneityMichael Platten
Neuro-Oncology|October 20, 2019
Driving mesenchymal transition in glioblastomaMichael Platten
Neuro-Oncology|October 24, 2017
EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?Michael Platten
Current Opinion in Neurology|September 8, 2025
Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?Michael Platten
Neuro-Oncology|December 17, 2021
How mutant isocitrate dehydrogenase orchestrates immune cellsLukas Bunse, Michael Platten
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Vaccines Targeting Gliomas: Antigens MatterMichael Platten, Niklas Grassl
The New England Journal of Medicine|January 8, 2025
Heating Up IDH-Mutant GliomasMichael Platten, Lukas Bunse
Neuro-Oncology|February 14, 2014
CMV infection and glioma, a highly controversial concept struggling in the clinical arenaWolfgang Wick, Michael Platten
Pageof 36